FDA Clears Aredia for Use in Treating Bone Metastases of Breast Cancer

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 5 No 9
Volume 5
Issue 9

ROCKVILLE, Md--The FDA has cleared Chiron Therapeutics' Aredia (pamidronate disodium for injection) for the treatment of patients with osteolytic bone metastases of breast cancer, in conjunction with standard antineoplastic therapy.

ROCKVILLE, Md--The FDA has cleared Chiron Therapeutics' Aredia(pamidronate disodium for injection) for the treatment of patientswith osteolytic bone metastases of breast cancer, in conjunctionwith standard antineoplastic therapy.

The drug has been on the market since 1991 and is also indicatedfor the treatment of osteolytic bone lesions of multiple myeloma,moderate-to-severe hypercalcemia of malignancy, and moderate-to-severePaget's disease.

Recent Videos
Breast oncologist Jade E. Jones, MD, says she tries to send patients with BRCA-mutant HR-positive TNBC to clinical trials that use PARP inhibitors.
Following progression on a CDK4/6 inhibitor, ascertaining the endocrine sensitivity of HR-positive/HER2-negative disease may inform sequential treatment.
T-DXd improved progression-free survival over standard chemotherapy among patients with HR-positive/triple-negative breast cancer in DESTINY-Breast04.
The use of chemotherapy trended towards improved recurrence-free intervals in older patients with high-risk tumors as determined via the MammaPrint assay.
Use of a pharmacist-directed resource appears to improve provider confidence and adverse effect monitoring for patients undergoing infusion therapy.
Reshma L. Mahtani, DO, describes how updates from the DESTINY-Breast09, ASCENT-04, and VERITAC-2 trials may shift practices in the breast cancer field.
Multidisciplinary care can help ensure that treatment planning does not deviate from established guidelines for inflammatory breast cancer management.
Related Content